Lyra Therapeutics. has been granted a patent for a coated scaffold designed to treat chronic sinusitis. This scaffold, made of polymeric strands and coated with a crosslinked elastomer, delivers mometasone furoate for at least 12 weeks, improving sinus patency and serving as an alternative to sinus surgery. GlobalData’s report on Lyra Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Lyra Therapeutics, was a key innovation area identified from patents. Lyra Therapeutics's grant share as of June 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Coated scaffold for treating chronic sinusitis
The patent US12036337B2 describes a coated scaffold designed to conform to the shape of the middle meatus space, which is a critical area in the nasal cavity. The scaffold consists of a plurality of polymeric strands made from a polymer material, specifically poly(lactide-co-glycolide) or similar biodegradable polymers. It features a coating of crosslinked elastomer, which enhances its structural integrity. A significant aspect of the invention is the inclusion of a topcoat containing mometasone furoate, configured to release the drug over a period of at least 12 weeks following its placement. This sustained release is intended to provide therapeutic benefits in managing conditions affecting the nasal passages.
Further claims detail the composition and properties of the scaffold and its coating. The elastomer material can include poly(lactide-co-caprolactone) with specific molar percentages of its components. The scaffold is designed to recover its shape significantly after being compressed, demonstrating its resilience and adaptability. Additionally, the scaffold can be loaded into a delivery catheter for ease of application. The claims also specify various dimensions for the scaffold, indicating its versatility in fitting different anatomical spaces within the middle meatus. Overall, the patent outlines a novel approach to delivering medication in a targeted manner while providing structural support in the nasal cavity.
To know more about GlobalData’s detailed insights on Lyra Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
